Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use

NCT02197598 | Completed Phase 4

• 2 other identifiers: 15871A2014-000413-31
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this study is to explore the treatment effects of Selincro in alcohol dependent patients with liver impairment.

Conditions

Alcohol Dependence

Keywords

nalmefene, alcohol consumption, liver effects

Outcome Measures

Primary Outcomes (16)

• Change from baseline in the number of heavy drinking days per month (HDDs) (days/month)

  Baseline to months 1, 2 and 3

• Change from baseline in the number of HDDs per week (days/week)

  Baseline to weeks 1 and 2

• Change from baseline in total alcohol consumption (TAC) (g alcohol/day)

  Baseline to months 1, 2 and 3

• Change from baseline in TAC (g alcohol/day)

  Baseline to weeks 1 and 2

• Response Shift Drinking Risk Level (RSDRL)

  Defined as a downward shift from baseline in drinking risk level (DRL); for patients with a very high DRL at baseline, a shift to medium DRL or lower; for patients with a high DRL at baseline, a shift to low DRL or below

  Baseline to month 3

• Response Low Drinking Risk Level (RLDRL)

  Defined as a downward shift from baseline in DRL to low DRL or below

  Baseline to month 3

• Response defined as ≥70% reduction in TAC

  Baseline to month 3

• Response defined as 0 to 4 HDDs (days/month)

  Month 3

• Clinical Global Impression, global improvement (CGI-I).

  Weeks 4 and 12

• Change from baseline in Clinical Global Impression, Severity of illness (CGI-S)

  Baseline to weeks 4 and 12

• Change in the Short-Form 36-Item Health Survey (SF-36)

  Baseline to week 12

• Change in liver stiffness

  Baseline to weeks 1,2 4 and 12

• Category shift in fibrosis stage

  Baseline to weeks 1,2 4, and 12

• Change in transaminases and γ-glutamyl transferase (γGT)

  Baseline to weeks 1,2,4,8, and 12

• Change in bilirubin, albumin, and International Normalized Ratio (INR)

  Baseline to weeks 1,2,4,8, and 12

• Number of adverse events

  Screening to week 14

Study Arms (1)

Selincro® (nalmefene) 18 mg, tablets

EXPERIMENTAL

One tablet orally for 12 weeks on days when the patient perceives a risk of drinking alcohol, preferably 1-2 hours prior to the anticipated risk of drinking.

Drug: nalmefene

Interventions

nalmefene DRUG

Also known as: Selincro®

Selincro® (nalmefene) 18 mg, tablets

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient has alcohol dependence, diagnosed at screening according to DSM-IV-TR™
• The patient has liver impairment defined by elevated liver stiffness and elevated liver enzymes at the Screening Visit (both criteria have to be fulfilled): liver stiffness (LS) as measured by Fibroscan \>6 kPa, elevated transaminases (AST or ALT). Transaminase levels up to 5 times the upper limit of the reference range and γGT levels up to 10 times the upper limit of the reference range are allowed. At the discretion of the investigator, transaminase levels \>5 times the upper limit of the reference range and γGT \>10 times the upper limit of the reference range can be allowed if considered habitual for the patient, either confirmed by patient records or a repeat measurement during the Screening Period
• The patient has a breath alcohol concentration (BrAC) \<0.02% at the Screening Visit.
• The patient provides a stable address and telephone number
• The patient is a man or woman, aged ≥ 18 years
• The patient has BMI≤30 kg/m2

You may not qualify if:

• The patient has any psychiatric disorder or Axis I disorder (DSM-IV-TR™ criteria), established as the primary diagnosis, other than alcohol dependence assessed using the Mini International Neuropsychiatric Interview (MINI) or another diagnostic interview , that in any way will interfere with the ability of the patient to take part in the study
• The patient has reported current use of, or has been tested positive for, drugs of abuse (opiates, methadone, cocaine, amphetamines \[including ecstasy\], barbiturates)
• The patient has severe liver impairment classified with a Child-Pugh Score C
• The patient has one or more clinical laboratory test values outside the reference range, based on the blood and urine samples taken at the Screening Visit, that are of potential risk to the patient's safety, or the patient has: Severe renal impairment (eGFR \<30 mL/min per 1.73 m2), and/or Hypercholesterolemia with serum cholesterol levels \> 300 mg/dL, (\>7,758 mmol/L), and/or bilirubin \> 3 mg/dL (50 μmol/L)
• The patient has had \<6 heavy drinking days (HDDs, defined by the European Medicines Agency as a day with an alcohol consumption \>60 g for men or \>40 g for women) in the 4 weeks preceding the Screening Visit
• The patient has \>5 consecutive abstinence days in the 4 weeks preceding the Screening Visit
• The patient has a recent history of acute alcohol withdrawal syndrome (including hallucinations, seizures, or delirium tremens)

Sponsors & Collaborators

• H. Lundbeck A/S: lead

Study Sites (3)

DE001

Heidelberg, Germany

Location

DE002

Mannheim, Germany

Location

Optuminisight

München, Germany

Location

MeSH Terms

Conditions

Alcoholism; Alcohol Drinking

Interventions

nalmefene

Condition Hierarchy (Ancestors)

Alcohol-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Drinking Behavior; Behavior

Study Officials

• Email contact via H.Lundbeck A/S

  LundbeckClinicalTrials@lundbeck.com

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 21, 2014
• First Posted: July 22, 2014
• Study Start: September 1, 2014
• Primary Completion: December 1, 2015
• Last Updated: December 14, 2016

Record last verified: 2016-12

Locations

DE (3)